U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07330076) titled 'Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors' on Dec. 29, 2025.
Brief Summary: The primary objective is to evaluate the efficacy and safety of Iruplinalkib Tablets as postoperative adjuvant therapy in patients with stage IA, ALK-positive NSCLC with high-risk factors.
Study Start Date: Jan. 06
Study Type: INTERVENTIONAL
Condition:
NSCLC
Intervention:
DRUG: Iruplinalkib tablets
Iruplinalkib: Refer to the drug insert. The tablets should be swallowed whole and must not be crushed, divided, or chewed. The recommended dosage is once daily, which can be taken on an empt...